angiotensin ii has been researched along with Disease Resistance in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castiglione, GM; Duh, EJ; Hung, CF; Neiman, Z; Xu, Z; Zhou, L | 1 |
| Gallego-Delgado, J; Rodriguez, A; Walther, T | 1 |
2 other study(ies) available for angiotensin ii and Disease Resistance
| Article | Year |
|---|---|
Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2.
Topics: Amino Acids; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Binding Sites; COVID-19; Disease Resistance; Dogs; Epistasis, Genetic; Evolution, Molecular; Gene Frequency; Humans; Hydrolysis; Mice; Mutation; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Virus Attachment | 2021 |
The High Blood Pressure-Malaria Protection Hypothesis.
Topics: Africa; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Asia; Causality; Disease Resistance; Drug Evaluation, Preclinical; Endemic Diseases; Endothelium, Vascular; Humans; Hypertension; Malaria, Cerebral; Malaria, Falciparum; Mice; Models, Biological; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Prevalence; Receptor, Angiotensin, Type 2; Selection, Genetic | 2016 |